Steinert clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
open to eligible people ages 16 years and up
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
at UCSD
Last updated: